Jeff Hixon

Jeff Hixon has a strong background in biochemistry and biophysics, with extensive experience in the pharmaceutical and biotech industries. Jeff is currently the Senior Vice President of Strategy and Operations at Scaffold Therapeutics, a position they have held since February 2023. Prior to this, Jeff held various roles at Faze Medicines, including Senior Director of Biochemistry & Biophysics, Head of Lead Identification, Interim Head of Drug Discovery, and Director of Biochemistry & Biophysics, Head of Lead Identification. Jeff worked at Faze Medicines from May 2020 until February 2023. Before joining Faze Medicines, Jeff worked at KSQ Therapeutics as the Director of Biochemistry from September 2018 to May 2020, and as the Associate Director of Biochemistry & Enzymology from July 2016 to September 2018. Jeff also gained experience at Agios Pharmaceuticals as a Senior Scientist in Biochemistry & Enzymology from February 2009 to July 2016. Jeff's career began at Millennium Pharmaceuticals, where they worked as a Senior Research Associate from 1996 to 2001. Jeff then moved on to Elixir Pharmaceuticals, where they served as a Research Investigator in Biochemistry & Assay Development from August 2002 to February 2009. Prior to that, Jeff worked as a Senior Research Associate at Essential Therapeutics from August 2001 to June 2002. Overall, Jeff has a diverse background in biochemistry and biophysics, with a focus on drug discovery and development in the field of cellular metabolism, particularly in the areas of cancer and rare genetic metabolic diseases.

Jeff Hixon studied at the University of New Hampshire, specializing in microbiology and biochemistry. No information is available regarding the specific years of their education or the degree they obtained.